AzTrials
AzTrials

Diabetes MellitusPhase 4NCT00894270

Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees

A Phase 4 study testing Sterile air injection and Novofine needle in people with Diabetes Mellitus, run by Liggins Institute at 1 site in New Zealand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Children and adolescents with type 1 diabetes mellitus are required to inject insulin daily. The injection technique should reliably deposit insulin into subcutaneous fat while minimizing inadvertent delivery into either the skin or the underlying muscle, both of which are associated with suboptimal outcomes. Read more about this study

Who is it for?
Ages 6 years and older
Conditions the study is for
Diabetes Mellitus
What is being tested?
Sterile air injection and Novofine needle
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
240 participants
Where
1 siteNew Zealand
Study dates
Nov 2008to May 2009
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The subject/parent will give signed Informed Consent before any trial related activities. If the parents sign, it will be secured verbally or in older children in writing that they fully agree to participate.
  • Type 1 children aged ≥ 6 and < 19 years. Puberty will be determined by a trained paediatric endocrinologist using standard Tanner Staging.
  • Type 1 and 2 diabetic adults aged > 19 years and ≤ 85 years.

Who cannot join

  • Skin disease at abdomen and/or thigh.
  • Lipohypertrophy at the site of injection.
  • Any musculoskeletal abnormalities.
  • Psychiatric disorders.

Trial locations and contacts

1 site in 1 country.

New Zealand1 site
  • Liggins Institute

    Auckland, Auckland, 1001

Other trials in New Zealand

About this study

Children and adolescents with type 1 diabetes mellitus are required to inject insulin daily. The injection technique should reliably deposit insulin into subcutaneous fat while minimizing inadvertent delivery into either the skin or the underlying muscle, both of which are associated with suboptimal outcomes. The use of shorter, thinner needles reduces the incidence of intramuscular delivery and is associated with reduced discomfort, but increases the risks of both shallow (intradermal) delivery and of loss of insulin through backflow to the skin surface.

In the current study, 240 subjects (children and adults) will receive multiple injections of small volumes of sterile air in the thigh and abdomen using 5 mm Novofine® needles, to simulate insulin injections performed at the two sites using various injection techniques (perpendicular or angled needle, with or without skin fold). Ultrasound visualisation of the injected air will allow determination of the incidence of intradermal or intramuscular delivery using the various delivery methods in the trial. In addition, adult subjects will receive injections of a liquid test medium in order to determine the incidence and extent of backflow. Qualitative data on perceived discomfort and information on body composition will also be collected. This investigation will form the basis for recommendations regarding preferred injection technique where 5 mm needles are used.

Read the detailed description

Rationale:

The injection techniques used with children and adolescents with type 1 diabetes mellitus should reliably deposit insulin into subcutaneous fat while minimizing inadvertent intramuscular (IM) insulin injections. Surprisingly, injection technique varies among centres, tends to be protocol driven and is usually dependent on needle length. The recommended injection procedure for diabetic children in our centre include a lifted or pinched skin fold either on the abdomen, thigh or buttocks with perpendicular injection of 8 mm syringes and angled injection of 12.7 mm syringes. However both 8 and 12.7 mm needles, have been associated with frequent IM injections with rates of 38% and 86% respectively, reported using a perpendicular insertion (1, 2). IM injection of regular, NPH and glargine insulin has been associated with more rapid insulin release, variability in glycaemic control and an increased risk of hypoglycaemia (3-5).

The risk of IM insulin deposition is known to be related to a number of variables including younger age, male sex, lower body mass index (BMI), injection technique (angle of insertion and a lifted or pinched skinfold), and needle length (1, 2, 6-8). Reducing the length of the insulin needle reduces the incidence of IM injections, however the use of 5 mm insulin needles may result in insulin being administered too superficially in the dermal layer (9, 10). The consequence of intradermal insulin deposition is largely unknown, but may lead to increased insulin leakage, increased injection pain, and an increased immune response (10). Little information is known about skin thickness, although it does vary with age, obesity and puberty (personal observations).

Smaller, thinner needles are also associated with reduced pain and discomfort. However they may cause greater insulin loss after the injection. This latter issue may also reflect the injection technique used with anecdotal evidence suggesting angled techniques may reduce insulin loss.

Objectives:

Primary Objective: To locate and compare simulated insulin injections in children, adolescents and adults with diabetes given with 5 mm needle using a 45 degree and 90 degree injection angle, with and without skin fold in order to provide injection guidelines.

Secondary Objectives:

  1. To study the thickness of dermis in abdomen and thigh in children, adolescents and adults with normal weight and over weight/obese.
  2. To evaluate the distance from skin surface to muscle fascia (abdomen/thigh) with and without compression of the skin in children, adolescents and adults with normal weight and over weight/obese.
  3. To quantify the amount of backflow of the test medium to the skin surface in adults and investigate whether there is a substantial clinically relevant difference among various techniques.
  4. To assess comfort and ease of injection technique

This trial is a single-centre and open-label phase IV trial. The investigation will be performed in three visits. Patients screening will be done at the first visit, 2 ± 1 days prior to the second visit day. The second and the third visit will be performed with two weeks ± 3 days apart. At the second visit day all the subjects will receive (performed by study nurse) injected sterile air corresponding to 20 IU of insulin (200 µl) with Novofine 5 mm needles perpendicularly in abdomen and thigh with and without skin fold, giving in total four injections at this visit. Following the injection, sterile air deposition will be visualized by ultra sound (GELogic5 or a Phillips IU-22 machine). A 12.5 MHz linear array transducer will be used. This measures depth up to 3cm accurately. To assess dermis and air after injections a 1cm standoff will be employed. This is standard ultrasound technique to examine changes close to the transducer and we developed expertise using this technique during our previous study. Because of the better visualization using a standoff smaller, more physiological, volumes of air can be reliably injected. Thickness of (i) dermis and (ii) distance from skin surface to muscle fascia at the respective injection places will also be measured by ultrasound both with and without lifted skin fold prior to injection. The adults will be then injected with 200 µl of test medium with a 5 mm needle perpendicularly in abdomen and thigh with a lifted skin fold, providing an additional four injections to the adults. Possible backflow to skin surface will be absorbed by filter paper and quantified by scale. Injection speed will be measured by time from start to end of injection. After each injection subjects will be asked to complete a visual analog pain scale and after the injections they will be asked their preference for needle technique and site of injection. On the third visit day all subjects will be injected 200µl sterile air (performed by study nurse) with 5 mm needles at 45degrees with and without pinch-up technique in the abdomen and thigh, providing a total of four injections to each subject. In addition, 200µl test medium with 5 mm needle at 45degrees in abdomen and thigh with and without lifted skin fold will be injected to adults. Possible backflow to skin surface will be absorbed by filter paper and quantified by scale. The weighing scale must be able to measure with three decimals in the metric system (microgram). A 10 cm visual analog pain scale will be used to assess the discomfort of the injections in comparison to standard injections.

Being tested
Sterile air injection, Placebo injection, Novofine needle
Keywords
Diabetes, Injection, Needle
Medical subject headings
Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sterile air injectionProcedure or surgery

    Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.

  • Placebo injectionProcedure or surgery

    Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.

  • Novofine needleDevice

    Novofine 5mm needle

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold.

    Measured: Assessed at the time of the injection

Secondary outcomes (2)
  1. Examine leakage of placebo medium from thigh or abdomen.

    Measured: Immediately following the injection

  2. Examine pain/discomfort of injections using the different techniques and the different injection sites.

    Measured: Immediately following the injection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2009 (estimated)
  2. Study startNov 2008
  3. Primary completionMay 2009
  4. Study completionMay 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
240 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00894270
Sponsor's protocol ID
Novofine002
Status last verified
May 2009
First submitted
5 May 2009
Last updated
8 May 2009
Results posted
No
Data monitoring committee
No

Publications

  • Hofman PL, Lawton SA, Peart JM, Holt JA, Jefferies CA, Robinson E, Cutfield WS. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med. 2007 Dec;24(12):1400-5. doi: 10.1111/j.1464-5491.2007.02272.x.

    PubMed 18042081

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Sterile air injection and Novofine needle in people with Diabetes Mellitus, run by Liggins Institute at 1 site in New Zealand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold. (time frame: Assessed at the time of the injection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00894270, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in